Why Novavax and Pfizer Are Trouncing the Market Today

·2-min read
Why Novavax and Pfizer Are Trouncing the Market Today

On yet more worrying news about the omicron variant of the coronavirus, the fortunes of coronavirus stocks were mixed on Tuesday. In contrast the co-developer of Pfizer's jab, BioNTech (NASDAQ: BNTX), was down by almost 3%. It's interesting that the fortunes of partners Pfizer and BioNTech, which together developed the Comirnaty vaccine, were diverging so sharply.

Our goal is to create a safe and engaging place for users to connect over interests and passions. In order to improve our community experience, we are temporarily suspending article commenting